RE: RE: Uricidin Peak $100 mil Beech...are you saying that Endo is intentionally downplaying Urocidin's potential by 400% in the refractory market alone???
That is shocking stuff...Don't be surprised if our wholly independent and 100% shareholder-centric board comes to us one day soon with an offer to ponder based on that 100 mil figure, 1 year's revenue figure though. $2 a share for human health...Thats a no brainer isn't it?
I have the utmost faith that my interests are in good hands...I'll take it!